Comparar métodos
Examine os métodos selecionados lado a lado; as linhas que diferem ficam destacadas.
| Quality-Adjusted Life Year (QALY)× | Análise de Custo-Efetividade (ACE)× | |
|---|---|---|
| Área | Economia da saúde | Economia da saúde |
| Família | Process / pipeline | Process / pipeline |
| Ano de origem≠ | 1985 | 1984 |
| Autor original≠ | Alan Williams (Health Economics Research Centre, Oxford University) | Drummond & Stoddart (Health Economics Research Group, McMaster University) |
| Tipo | Method | Method |
| Fonte seminal≠ | Kind, P. (1989). The EuroQol instrument: an index of health-related quality of life. In B. Teeling Smith (Ed.), Measuring health: a practical approach. Chichester: Wiley. link ↗ | Gold, M. R., Siegel, J. E., Russell, L. B., & Weinstein, M. C. (Eds.). (1996). Cost-Effectiveness in Health and Medicine. New York: Oxford University Press. link ↗ |
| Outros nomes≠ | QALY, health utility measure | CEA, ICER, Incremental Cost-Effectiveness Ratio |
| Relacionados | 5 | 5 |
| Resumo≠ | A QALY measures health benefit as utility weight (0 = death, 1 = perfect health) multiplied by time lived. Developed by Alan Williams in 1985, QALYs enable comparison of disparate health interventions on a common metric. Used globally by health technology assessment bodies—NICE (UK), HAS (France), CADTH (Canada), WHO—to decide which treatments deserve public funding. | Cost-effectiveness analysis compares the incremental cost per unit of health benefit gained by one intervention relative to a comparator (standard care or best alternative). Developed rigorously in the 1980s by Drummond, Stoddart, and colleagues, CEA is now the standard framework for technology appraisal globally. NICE, HAS, CADTH, and other health technology assessment bodies use CEA to decide which treatments warrant public funding and at what price. |
| ScholarGateConjunto de dados ↗ |
|
|